Register
Login:
Share:
Email Facebook Twitter

Add Gw Pharmaceuticals to quick picks

Gw Pharmaceuticals Share Price (GWP)



Share Price Information for Gw Pharmaceuticals (GWP)


Share Price: 430.00Bid: 423.25Ask: 424.75Change: 10.25 (+2.44%)Riser - Gw Pharm.
Spread: 1.50Spread as %: 0.35%Open: 413.75High: 430.00Low: 416.25Yesterday’s Close: 419.75

Gw Pharmaceuticals Plc Ord 0.1P

Gw Pharmaceuticals is listed in the FTSE AIM 100, FTSE AIM UK 50, FTSE AIM All-Share
Gw Pharmaceuticals is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
430.00

Share Price SpacerBid
423.25

Share Price SpacerAsk
424.75

Share Price SpacerChange
2.44%10.25

Share Price SpacerVolume
410,232

Share Price SpacerOpen
413.75

Share Price SpacerHigh
430.00

Share Price SpacerLow
416.25

Share Price SpacerClose
419.75

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 236.69m £1,017.75m 3,000

52 Week High 541.00 52 Week High Date 1-JUL-2014
52 Week Low 151.00 52 Week Low Date 10-DEC-2013

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
647 208,358 200,769 -143.333 -3.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

24-Nov-14
17:14:14
419.25
1,289
Sell* 
423.25
424.75
5,404
Trade Type:
Ordinary
Bargain conditions apply

24-Nov-14
17:12:54
423.1439
7,143
Sell* 
423.25
424.75
30.23k
Trade Type:
Ordinary
Bargain conditions apply

24-Nov-14
17:08:48
425.2372
752
Buy* 
423.25
424.75
3,198
Trade Type:
Ordinary
Bargain conditions apply


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Gw Pharmaceuticals trades >>

Directors Deals for Gw Pharmaceuticals (GWP)
Trade DateActionNotifierPriceCurrencyAmountHolding
29-Aug-14Transfer To
Trade Notifier Information for GW Pharmaceuticals
Geoffrey Guy held the position of Executive Chairman at GW Pharmaceuticals at the time of this trade.
 Geoffrey Guy
0175,00014443648
26-Nov-13Transfer To
Trade Notifier Information for GW Pharmaceuticals
Justin Gover held the position of Managing Director at GW Pharmaceuticals at the time of this trade.
 Justin Gover
0500,0003483368
30-Sep-13Notification of Holding
Trade Notifier Information for GW Pharmaceuticals
Christopher John Tovey held the position of Chief Operating Officer at GW Pharmaceuticals at the time of this trade.
 Christopher John Tovey
000
View more Gw Pharmaceuticals directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 12:45
kingskin
RE: Q4
421.50
No Opinion

finally!! i think any drop will be made back up by the end of the day, based on recent trading patterns, last time we saw a drop of about 15p, which it quickly bounced back from.
Today 12:41
kingskin
RE: 'anecdotal' cancer cure
418.25
No Opinion

absolutely, im not the one saying it, JG did during the jefferies presentation....which seemed odd, hence why it is beyond me that he would say such a thing..(unless its politics) have a listen.. http://ir.gwpharm.com/events.cfm
Today 09:43
FlowerPowerBob
RE: 'anecdotal' cancer cure
424.00
No Opinion

GW do have an interest in THC, Sativex has THC in it doesn't it?
Today 09:42
FlowerPowerBob
RE: Tv coverage
424.00
No Opinion

Thanks for the tip-off on this TV programme. The GW clinical trials on Epidiolex© are on around 8 minutes in but the whole thing is worth watching. http://www.aljazeera.com/programmes/techknow/2014/11/charlotte-web-201411211242018697.html
Today 07:53
bigbob0228
Q4
419.75
No Opinion

GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results and Host Conference Call on 2 December, 2014 LONDON, Nov. 24, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 2 December, 2014 its fourth quarter, year-end financial results for the period ending 30 September, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call. About GW Pharmaceuticals plc Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com. Enquiries: GW Pharmaceuticals plc(Today) +44 20 3727 1000 Justin Gover, Chief Executive Officer(Thereafter) + 44 1980 557000 Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570 FTI Consulting (Media Enquiries) Ben Atwell / Simon Conway / John Dineen (UK)+ 44 20 3727 1000 Robert Stanislaro (U.S.)212 850 5657 Trout Group, LLC (U.S. investor relations) Todd James / Chad Rubin646 378 2900 Source: GW Pharmaceuticals plc
Sat 13:15
kingskin
'anecdotal' cancer cure
419.75
No Opinion

quite few of these type of vids on the net, what i find interesting about this one is the 'backdoor' delivery method employed that reputedly reduced the psychoactive effects of the high strength THC, also she had no radiation therapy, worth a watch esp if you happen to be justin gover, how GWP can suggest that they have no interest in THC is beyond me*..all the evidence suggests it is highly theraputic, unlike politics, so who are we trying to help here, the patients or the politicians.... https://www.youtube.com/watch?v=-hUoyXKf81c&feature=youtu.be *JG made this comment during the jefferies presentation

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Gw Pharmaceuticals (GWP) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Gw Pharmaceuticals Plc Ord 0.1P home pageWebsite: Gw Pharmaceuticals Plc Ord 0.1P
Website Description: GW Pharmaceutical



Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.